AR045857A1 - Forma de dosis oral que comprende una prodroga de un inhibidor de la bomba de proton y uso de la prodroga de un inhibidor de la bomba de proton para preparar dicha forma de dosis - Google Patents
Forma de dosis oral que comprende una prodroga de un inhibidor de la bomba de proton y uso de la prodroga de un inhibidor de la bomba de proton para preparar dicha forma de dosisInfo
- Publication number
- AR045857A1 AR045857A1 ARP040103586A ARP040103586A AR045857A1 AR 045857 A1 AR045857 A1 AR 045857A1 AR P040103586 A ARP040103586 A AR P040103586A AR P040103586 A ARP040103586 A AR P040103586A AR 045857 A1 AR045857 A1 AR 045857A1
- Authority
- AR
- Argentina
- Prior art keywords
- prodrug
- proton pump
- pump inhibitor
- membrane permeability
- dose form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una forma de doble oral que comprende una prodroga de un inhibidor de la bomba de protón, dicha prodroga tiene una permeabilidad de membrana y dicho inhibidor de la bomba de protón tiene una permeabilidad de membrana, donde la permeabilidad de membrana del inhibidor de la bomba de protón es más que dos veces la permeabilidad de membrana de la prodroga, y dicha forma de dosis tiene un pH desde 3 a 9. Preferentemente, dicha prodroga no está entéricamente revestida. La prodroga puede comprender un ácido carboxílico o una sal farmacéuticamente aceptable de la misma, una fracción de sulfonilo, una fracción de fenilsulfonilo, o una fracción de fenilsulfonilo y un ácido carboxílico o una sal farmacéuticamente aceptable de los mismos. El inhibidor de la bomba de protón puede ser seleccionado de lansoprazol, esomeprazol, omebrazol, pantoprazol y rabeprazol. La forma de dosis puede comprende una mezcla de la prodroga y el inhibidor de la bomba de protón, en donde preferentemente la permeabilidad de membrana del inhibidor de la bomba de protón es más que dos veces la permeabilidad de membrana de la prodroga. Uso de una prodroga de un inhibidor de la bomba de protón para preparar una forma de dosis según lo descripto siendo de utilidad en un método para tratar una enfermedad o una condición adversa que afecta el tracto gastrointestinal en una persona, especialmente para inhibir la secreción del ácido gástrico en una persona, mediante la administración en forma oral a dicha persona de dicha prodroga. Más preferentemente aún, la forma de dosis comprende: una fórmula (1), o una sal farmacéuticamente aceptable de los mismos donde: A es H, OCH3, o OCHF2; B ES CH3 o OCH3; D es OCH3, OCH2, CF3, o O(CH2)3OHC3; E es H o CH3; R1, R2, R3 y R5 son independientemente H, CH3, CO2H, CH2CO2H, (CH2)2CO2H; CH(CH3)2, OCH2C(CH3)2CO2H, OCH2CO2CH3, OCH2CO2H, OCH2CO2HN2, OCH2CONH2(CH2)5CO2CH3, o CH3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50835603P | 2003-10-03 | 2003-10-03 | |
| US51388003P | 2003-10-22 | 2003-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045857A1 true AR045857A1 (es) | 2005-11-16 |
Family
ID=34437281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103586A AR045857A1 (es) | 2003-10-03 | 2004-10-01 | Forma de dosis oral que comprende una prodroga de un inhibidor de la bomba de proton y uso de la prodroga de un inhibidor de la bomba de proton para preparar dicha forma de dosis |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050075371A1 (es) |
| EP (1) | EP1670467A1 (es) |
| JP (1) | JP2007518700A (es) |
| KR (1) | KR20060082082A (es) |
| AR (1) | AR045857A1 (es) |
| AU (1) | AU2004279378A1 (es) |
| BR (1) | BRPI0415044A (es) |
| CA (1) | CA2540977A1 (es) |
| IL (1) | IL174265A0 (es) |
| MX (1) | MXPA06003461A (es) |
| NO (1) | NO20061354L (es) |
| TW (1) | TW200522956A (es) |
| WO (1) | WO2005034951A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070060621A1 (en) * | 2004-02-18 | 2007-03-15 | Hughes Patrick M | Methods and compositions for the administration of prodrugs of proton pump inhibitors |
| JP2007523164A (ja) * | 2004-02-18 | 2007-08-16 | アラーガン、インコーポレイテッド | プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物 |
| WO2007081871A1 (en) * | 2006-01-10 | 2007-07-19 | Allergan, Inc. | Therapeutic salt compositions of sulfonyl ester prodrugs of proton pump inhibitors and methods for their preparation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| SE8505112D0 (sv) * | 1985-10-29 | 1985-10-29 | Haessle Ab | Novel pharmacological compounds |
| FI90544C (fi) * | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| CA2083606C (en) * | 1990-06-20 | 2001-08-21 | Arne Elof Brandstrom | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
| CN100396675C (zh) * | 1998-08-10 | 2008-06-25 | 加利福尼亚州大学董事会 | 质子泵抑制剂的前药 |
| WO2004009583A2 (en) * | 2002-07-19 | 2004-01-29 | Garst Michael E | Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor |
| NZ544173A (en) * | 2003-07-15 | 2009-04-30 | Alevium Pharmaceuticals Inc | Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors |
-
2004
- 2004-09-17 US US10/943,411 patent/US20050075371A1/en not_active Abandoned
- 2004-09-29 TW TW093129421A patent/TW200522956A/zh unknown
- 2004-10-01 AR ARP040103586A patent/AR045857A1/es not_active Application Discontinuation
- 2004-10-01 JP JP2006534083A patent/JP2007518700A/ja active Pending
- 2004-10-01 MX MXPA06003461A patent/MXPA06003461A/es not_active Application Discontinuation
- 2004-10-01 EP EP04785301A patent/EP1670467A1/en not_active Withdrawn
- 2004-10-01 WO PCT/US2004/032099 patent/WO2005034951A1/en active Application Filing
- 2004-10-01 BR BRPI0415044-9A patent/BRPI0415044A/pt not_active IP Right Cessation
- 2004-10-01 CA CA002540977A patent/CA2540977A1/en not_active Abandoned
- 2004-10-01 AU AU2004279378A patent/AU2004279378A1/en not_active Abandoned
- 2004-10-01 KR KR1020067006439A patent/KR20060082082A/ko not_active Application Discontinuation
-
2006
- 2006-03-12 IL IL174265A patent/IL174265A0/en unknown
- 2006-03-24 NO NO20061354A patent/NO20061354L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL174265A0 (en) | 2006-08-01 |
| JP2007518700A (ja) | 2007-07-12 |
| US20050075371A1 (en) | 2005-04-07 |
| TW200522956A (en) | 2005-07-16 |
| EP1670467A1 (en) | 2006-06-21 |
| AU2004279378A1 (en) | 2005-04-21 |
| WO2005034951A1 (en) | 2005-04-21 |
| MXPA06003461A (es) | 2006-06-05 |
| CA2540977A1 (en) | 2005-04-21 |
| KR20060082082A (ko) | 2006-07-14 |
| NO20061354L (no) | 2006-05-03 |
| BRPI0415044A (pt) | 2006-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2252032C2 (ru) | Новое применение соединений в качестве антибактериальных средств | |
| RU96120189A (ru) | Новые фармацевтические препараты и способы их получения | |
| US6605303B1 (en) | Oral pharmaceutical extended release dosage form | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| JP2003500442A5 (es) | ||
| SK172000A3 (en) | Self-emulsifying formulation for lipophilic compounds | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| KR20110135428A (ko) | 동통 치료용 ＩκＢ 키나제 억제제의 용도 | |
| AU2005202553A1 (en) | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | |
| RU2002122744A (ru) | Новая самоэмульгирующаяся система доставки лекарств | |
| MEP10808A (en) | Solid drug for oral use | |
| RU2007141655A (ru) | Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний | |
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| RU2012123603A (ru) | Фармацевтическая пероральная твердая препаративная форма, способ ее получения, способ лечения или предупреждения заболеваний пищеварительной системы с ее помощью, лекарственное средство, таблетка, капсула или саше на ее основе | |
| CY1109939T1 (el) | Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου | |
| CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
| JP2003512327A5 (es) | ||
| BG65580B1 (bg) | Течен състав със заместени бензимидазоли | |
| ES2511792T3 (es) | Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP | |
| AR045857A1 (es) | Forma de dosis oral que comprende una prodroga de un inhibidor de la bomba de proton y uso de la prodroga de un inhibidor de la bomba de proton para preparar dicha forma de dosis | |
| RU2007132704A (ru) | Органические соединения | |
| JP2019077615A (ja) | 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤 | |
| CA2474246A1 (en) | Alkylammonium salts of omeprazole and esomeprazole | |
| RU2006135552A (ru) | Способы и составы для лечения заболеваний, связанных с helikobakter pyroli. с использованием соединений, содержащих эндопероксидный мостик |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |